BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 19443657)

  • 1. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
    Bartel TB; Haessler J; Brown TL; Shaughnessy JD; van Rhee F; Anaissie E; Alpe T; Angtuaco E; Walker R; Epstein J; Crowley J; Barlogie B
    Blood; 2009 Sep; 114(10):2068-76. PubMed ID: 19443657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review.
    van Lammeren-Venema D; Regelink JC; Riphagen II; Zweegman S; Hoekstra OS; Zijlstra JM
    Cancer; 2012 Apr; 118(8):1971-81. PubMed ID: 21887677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
    Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
    Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
    Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
    Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of
    Han S; Woo S; Kim YI; Yoon DH; Ryu JS
    Eur Radiol; 2021 Jan; 31(1):152-162. PubMed ID: 32809165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Evaluation of Magnetic Resonance Imaging and [
    Moreau P; Attal M; Caillot D; Macro M; Karlin L; Garderet L; Facon T; Benboubker L; Escoffre-Barbe M; Stoppa AM; Laribi K; Hulin C; Perrot A; Marit G; Eveillard JR; Caillon F; Bodet-Milin C; Pegourie B; Dorvaux V; Chaleteix C; Anderson K; Richardson P; Munshi NC; Avet-Loiseau H; Gaultier A; Nguyen JM; Dupas B; Frampas E; Kraeber-Bodere F
    J Clin Oncol; 2017 Sep; 35(25):2911-2918. PubMed ID: 28686535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients.
    Park S; Lee SJ; Chang WJ; Maeng CH; Hong JY; Choi MK; Kim YS; Jung CW; Jang JH; Kim SJ; Kim WS; Choi JY; Kim K
    Acta Haematol; 2014; 131(4):193-9. PubMed ID: 24296366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma?
    Caldarella C; Isgrò MA; Treglia I; Treglia G
    Int J Hematol; 2012 Dec; 96(6):685-91. PubMed ID: 23135876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT.
    Ak İ; Onner H; Akay OM
    Ann Hematol; 2015 Sep; 94(9):1567-75. PubMed ID: 26068066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The value of fluorodeoxyglucose positron emission tomography in multiple myeloma].
    Adam Z; Bolcák K; Stanícek J; Pour L; Hájek R; Krejcí M; Prásek J; Neubauer J; Mareschova Y; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):207-14. PubMed ID: 16722151
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Jung SH; Kwon SY; Min JJ; Bom HS; Ahn SY; Jung SY; Lee SS; Park MR; Yang DH; Ahn JS; Kim HJ; Lee JJ
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):107-115. PubMed ID: 30187105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement.
    Lapa C; Knop S; Schreder M; Rudelius M; Knott M; Jörg G; Samnick S; Herrmann K; Buck AK; Einsele H; Lückerath K
    Theranostics; 2016; 6(2):254-61. PubMed ID: 26877783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Baseline
    Moon SH; Choi WH; Yoo IR; Lee SJ; Paeng JC; Jeong SY; Lee SW; Kim K; Choi JY
    Korean J Radiol; 2018; 19(3):481-488. PubMed ID: 29713226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medullary Abnormalities in Appendicular Skeletons Detected With
    Abe Y; Narita K; Kobayashi H; Kitadate A; Takeuchi M; O'uchi T; Matsue K
    AJR Am J Roentgenol; 2019 Oct; 213(4):918-924. PubMed ID: 31216203
    [No Abstract]   [Full Text] [Related]  

  • 17. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.
    Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S
    In Vivo; 2008; 22(4):513-7. PubMed ID: 18712181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET increases visibility of bone lesions in relapsed multiple myeloma: is this hypoxia-driven?
    de Waal EG; Slart RH; Leene MJ; Kluin PM; Vellenga E
    Clin Nucl Med; 2015 Apr; 40(4):291-6. PubMed ID: 25546223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study.
    Bailly C; Carlier T; Jamet B; Eugene T; Touzeau C; Attal M; Hulin C; Facon T; Leleu X; Perrot A; Garderet L; Macro M; Caillot D; Moreau P; Kraeber-Bodéré F; Bodet-Milin C
    Clin Cancer Res; 2018 Nov; 24(21):5219-5224. PubMed ID: 30068709
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using
    Nakuz TS; Millinger FP; El-Rabadi K; Weber M; Pichler V; Wadsak W; Mitterhauser M; Haug A; Hacker M; Karanikas G; Pietschmann P; Agis H
    Anticancer Res; 2019 Apr; 39(4):1943-1952. PubMed ID: 30952737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.